| Molecular therapies and precision medicine for hepatocellular carcinoma JM Llovet, R Montal, D Sia, RS Finn Nature reviews Clinical oncology 15 (10), 599-616, 2018 | 1524 | 2018 |
| Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial R Pinyol, R Montal, L Bassaganyas, D Sia, T Takayama, GY Chau, ... Gut 68 (6), 1065-1075, 2019 | 224 | 2019 |
| Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC R Lencioni, R Montal, F Torres, JW Park, T Decaens, JL Raoul, M Kudo, ... Journal of hepatology 66 (6), 1166-1172, 2017 | 207 | 2017 |
| Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma R Montal, D Sia, C Montironi, WQ Leow, R Esteban-Fabró, R Pinyol, ... Journal of hepatology 73 (2), 315-327, 2020 | 198 | 2020 |
| Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival JM Llovet, R Montal, A Villanueva Journal of hepatology 70 (6), 1262-1277, 2019 | 177 | 2019 |
| Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020) PK Haber, M Puigvehí, F Castet, V Lourdusamy, R Montal, P Tabrizian, ... Gastroenterology 161 (3), 879-898, 2021 | 145 | 2021 |
| Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity A Moeini, D Sia, Z Zhang, G Camprecios, A Stueck, H Dong, R Montal, ... Journal of hepatology 66 (5), 952-961, 2017 | 141 | 2017 |
| Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials R Montal, C Andreu-Oller, L Bassaganyas, R Esteban-Fabró, S Moran, ... British journal of cancer 121 (4), 340-343, 2019 | 71 | 2019 |
| Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma L Bassaganyas, R Pinyol, R Esteban-Fabró, L Torrens, S Torrecilla, ... Clinical Cancer Research 26 (23), 6350-6361, 2020 | 42 | 2020 |
| Microenvironmental reactive oxygen species in colorectal cancer: involved processes and therapeutic opportunities MA Sorolla, I Hidalgo, A Sorolla, R Montal, O Pallisé, A Salud, E Parisi Cancers 13 (20), 5037, 2021 | 26 | 2021 |
| New drugs effective in the systemic treatment of hepatocellular carcinoma C Montironi, R Montal, JM Llovet Clinical liver disease 14 (2), 56-61, 2019 | 26 | 2019 |
| Objective response predicts survival in advanced hepatocellular carcinoma treated with systemic therapies M Kudo, R Montal, RS Finn, F Castet, K Ueshima, N Nishida, PK Haber, ... Clinical Cancer Research 28 (16), 3443-3451, 2022 | 25 | 2022 |
| Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies D Azuara, C Santos, A Lopez-Doriga, J Grasselli, M Nadal, X Sanjuan, ... Molecular Cancer Therapeutics 15 (5), 1106-1112, 2016 | 21 | 2016 |
| Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial R Pinyol, R Montal, T Takayama, GY Chau, V Mazzaferro, S Roayaie, ... Journal of Hepatology 66 (1), S12-S13, 2017 | 13 | 2017 |
| Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy A Rovira, J Tornero, M Oliva, M Taberna, R Montal, J Nogues, A Farre, ... Head & Neck 39 (1), 116-121, 2017 | 12 | 2017 |
| Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer V Ortiz-Barahona, M Soler, V Davalos, CA García-Prieto, M Janin, ... Molecular Cancer 22 (1), 83, 2023 | 9 | 2023 |
| Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab R Montal, M Oliva, M Taberna, L De Avila, A Rovira, M Cos, M Mañós, ... Clinical and Translational Oncology 18, 1140-1146, 2016 | 6 | 2016 |
| Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy CJ O'Rourke, M Salati, C Rae, G Carpino, H Leslie, A Pea, MG Prete, ... Gut 73 (3), 496-508, 2024 | 5 | 2024 |
| Prognostic factors involved in the epithelial–mesenchymal transition process in colorectal cancer have a preponderant role in oxidative stress: A systematic review and meta … E Parisi, A Sorolla, R Montal, R González-Resina, A Novell, A Salud, ... Cancers 12 (11), 3330, 2020 | 5 | 2020 |
| Reply to:“mRECIST for systemic therapies: More evidence is required before recommendations could be made” R Montal, R Lencioni, JM Llovet Journal of hepatology 67 (1), 196-197, 2017 | 5 | 2017 |
